Buntanetap Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Buntanetap Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
7
Registered trials
8
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Buntanetap can convert its Small molecule drug profile and APP x TAU x α-synuclein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Buntanetap (query alias: Buntanetap) |
|---|---|
| Modality / target | Small molecule drug; APP x TAU x α-synuclein; APP inhibitors, TAU inhibitors, α-synuclein inhibitors |
| Highest global status | Phase 3 |
| Originator | National Institute on Aging |
| Active developers | Annovis Bio, Inc. |
The MCP disease footprint includes Alzheimer Disease, Parkinson Disease, Lewy Body Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06709014 | Phase 3 | Active, not recruiting | 760 | Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) |
| NCT05357989 | Phase 3 | Completed | 523 | Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state) |
| NCT07284784 | Phase 2/3 | Recruiting | 500 | Safety of buntanetap |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease
Phase 2/3; n=351; evaluation: not stated. Reported fields: Change From Baseline to Week 12 in ADAS-Cog11(Least Squares Mean) = -2.32 units on a scale (Standard Error, 0.533); -; -
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Phase 3; n=523; evaluation: not stated. Reported fields: Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)(Least Squares Mean) = -0.10 units on a scale (Standard Error, 0.311); Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)(Least Squares Mean) = -0.04 units on a scale (Standard Error, 0.319); -
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: MDS-UPDRS = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline ; MDS-UPDRS = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Buntanetap addresses Alzheimer Disease, Parkinson Disease, Lewy Body Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-04-28 | Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor”. The milestone feed surfaced a patent-application signal described as “Solid state forms of buntanetap and process for preparation thereof”. The milestone feed surfaced a patent-application signal described as “Treatment of mental illness via administration of buntanetap and analogues thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
